Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) Director Jeffrey W. Albers sold 15,161 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total value of $1,660,584.33. Following the completion of the transaction, the director now owns 152,396 shares in the company, valued at approximately $16,691,933.88. This trade represents a 9.05 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Blueprint Medicines Stock Up 4.1 %
BPMC opened at $115.63 on Friday. The company has a market capitalization of $7.35 billion, a P/E ratio of -54.80 and a beta of 0.61. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. The firm’s fifty day moving average price is $95.28 and its two-hundred day moving average price is $95.48. Blueprint Medicines Co. has a fifty-two week low of $72.24 and a fifty-two week high of $121.90.
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The business had revenue of $128.20 million during the quarter, compared to analysts’ expectations of $127.56 million. During the same period in the prior year, the firm posted ($2.20) EPS. Blueprint Medicines’s quarterly revenue was up 126.5% compared to the same quarter last year. On average, analysts anticipate that Blueprint Medicines Co. will post -3.67 EPS for the current year.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on Blueprint Medicines
Institutional Trading of Blueprint Medicines
Several large investors have recently made changes to their positions in BPMC. Wellington Management Group LLP raised its stake in shares of Blueprint Medicines by 22.5% in the third quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company’s stock worth $366,726,000 after acquiring an additional 729,055 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Blueprint Medicines by 540.0% in the second quarter. Millennium Management LLC now owns 627,626 shares of the biotechnology company’s stock valued at $67,646,000 after purchasing an additional 529,566 shares in the last quarter. State Street Corp raised its position in Blueprint Medicines by 16.2% in the 3rd quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company’s stock worth $255,827,000 after purchasing an additional 385,818 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in Blueprint Medicines by 161.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 496,087 shares of the biotechnology company’s stock worth $45,888,000 after buying an additional 306,079 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in Blueprint Medicines by 79.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 501,581 shares of the biotechnology company’s stock valued at $54,060,000 after buying an additional 221,813 shares during the last quarter.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Recommended Stories
- Five stocks we like better than Blueprint Medicines
- How to Calculate Return on Investment (ROI)
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- What is Forex and How Does it Work?
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- Investing in the High PE Growth Stocks
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.